Seeking Alpha

Array (ARRY -14.8%) takes a pounding after its ARRY-797 drug failed to reduce pain better than...

Array (ARRY -14.8%) takes a pounding after its ARRY-797 drug failed to reduce pain better than an existing standard treatment, Oxycodone, in a Phase II trial of osteoarthritis patients. However, ARRY-797 did did meet its primary endpoints and reduced pain much more than a placebo. (PR)
Comments (1)
  • kuma
    , contributor
    Comments (2) | Send Message
     
    As an MD I can tell you that ARRAY 797, if it continues to prove to be as safe and as effective as it was in the recent study, then it will be a huge blockbuster of a drug. The ability to relieve pain as well as narcotics (the gold standard in pain relief) plus NSAIDS is phenomenal, particularly with fewer side-effects. I think ARRY is demonstrating that they know how to design drugs that work and surely pharmaceutical companies are going to line up to partner on such a potentially profitable new drug.
    1 Aug 2012, 12:59 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs